RecruitingPhase 1NCT06980649
Study of BHV-1300 in Graves' Disease
An Open-Label Biomarker Study of BHV-1300 in Graves' Disease
Sponsor
Biohaven Therapeutics Ltd.
Enrollment
15 participants
Start Date
Aug 21, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria1
- \. Participants must have serologically confirmed Graves' Disease.
Exclusion Criteria2
- History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter) and/or history of thyroid storm within six weeks of the Baseline visit.
- History of treatment with radioactive iodine or thyroid surgery.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGBHV-1300
BHV-1300 is delivered subcutaneously (SC)
Locations(13)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06980649
Related Trials
NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
NCT073058186 locations
Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease
NCT074807201 location
A Study of GensSci098 in Subjects With Graves' Disease
NCT072866561 location
Impact of Thyroid Hormones on Human Glucose and Energy Metabolism
NCT074106371 location
Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease
NCT073690631 location